Who owns the CYTOTIL trademark?

The CYTOTIL trademark is owned by Obsidian Therapeutics, Inc..

What class is the CYTOTIL trademark registered in?

The CYTOTIL trademark is registered in Class 042 (Scientific, technology & SaaS services).

What is the serial number for CYTOTIL?

The USPTO serial number for CYTOTIL is 97928862.

What is the registration number for CYTOTIL?

CYTOTIL is registered under USPTO registration number 8034801.

Sealvo

Home Search: CYTOTILCYTOTIL #97928862

Back

Updated Sep 24, 2026·9 searches this week

View on USPTO TSDR Find similar marks

CYT

USPTO Trademark Record

REGISTERED

CYTOTIL

SN 97928862·Reg 8034801·Filed May 10, 2023

Owner Obsidian Therapeutics, Inc.

Scientific and technological services and research and design relating thereto; industrial analysis, industrial research and industrial design services; quality control and authentication services; design and development of computer hardware and software.

CYTOTIL (Serial No. 97928862), Registration No. 8034801, is a registered US trademark filed on May 10, 2023 by Obsidian Therapeutics, Inc.. This trademark covers Class 042 (Scientific, technology & SaaS services).

early section 8: November 18, 2031

Conflict Analysis

Full conflict analysis for CYTOTIL (SN 97928862) against the USPTO database with detailed risk factor explanations. AI-powered — takes ~1-2 min.

Mark Intelligence

CYTOTIL (Reg. #8034801) is a registered US trademark that has been protecting its owner, Obsidian Therapeutics, Inc., since 2023. The mark covers Class 042 (Scientific, technology & SaaS services). Goods and services include Scientific and technological services and research and design relating thereto; industrial analysis, industrial research....

FILED

May 10, 2023

SERIAL

97928862

REG#

8034801

REGISTERED

Nov 18, 2025

Filing Information

StatusREGISTERED

Filing DateMay 10, 2023

Serial Number97928862

Registration No.8034801

Registration DateNov 18, 2025

Status DateNov 18, 2025

Mark TypeStandard characters

Filing Basis & Declarations

Standard Characters ClaimedUse Application CurrentlyTrademark

Full Goods & Services

CLASSES

OFFICE

USPTO

COUNTRY

Class 042Scientific, technology & SaaS services

US codes: 100, 101

First use anywhere: Sep 30, 2019

First use in commerce: Sep 30, 2019

This description is as filed with the USPTO and defines the scope of trademark protection.

Run a conflict check

Search by serial number, mark name, or logo. See conflicting marks ranked by risk with clear explanations of what contributed.

Run conflict check

Status History

39 events

REGISTERED-SUPPLEMENTAL REGISTER

Nov 18, 2025

REGISTERED-SUPPLEMENTAL REGISTER

NOTICE OF REGISTRATION CONFIRMATION EMAILED

Nov 18, 2025

NOTICE OF REGISTRATION CONFIRMATION EMAILED

APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER

Oct 16, 2025

APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER

EXAMINERS AMENDMENT -WRITTEN

Sep 26, 2025

EXAMINERS AMENDMENT -WRITTEN

EXAMINERS AMENDMENT E-MAILED

Sep 26, 2025

EXAMINERS AMENDMENT E-MAILED

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

Sep 26, 2025

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

EXAMINER'S AMENDMENT ENTERED

Sep 26, 2025

EXAMINER'S AMENDMENT ENTERED

SUBSEQUENT FINAL REFUSAL WRITTEN

Jul 09, 2025

SUBSEQUENT FINAL REFUSAL WRITTEN

SUBSEQUENT FINAL EMAILED

Jul 09, 2025

SUBSEQUENT FINAL EMAILED

NOTIFICATION OF SUBSEQUENT FINAL EMAILED

Jul 09, 2025

NOTIFICATION OF SUBSEQUENT FINAL EMAILED

TEAS RESPONSE TO OFFICE ACTION RECEIVED

May 21, 2025

TEAS RESPONSE TO OFFICE ACTION RECEIVED

CORRESPONDENCE RECEIVED IN LAW OFFICE

May 21, 2025

CORRESPONDENCE RECEIVED IN LAW OFFICE

TEAS/EMAIL CORRESPONDENCE ENTERED

May 21, 2025

TEAS/EMAIL CORRESPONDENCE ENTERED

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

Feb 19, 2025

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

Feb 19, 2025

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

USE AMENDMENT ACCEPTED

Nov 21, 2024

USE AMENDMENT ACCEPTED

NON-FINAL ACTION WRITTEN

Nov 21, 2024

NON-FINAL ACTION WRITTEN

NON-FINAL ACTION E-MAILED

Nov 21, 2024

NON-FINAL ACTION E-MAILED

NOTIFICATION OF NON-FINAL ACTION E-MAILED

Nov 21, 2024

NOTIFICATION OF NON-FINAL ACTION E-MAILED

TEAS REQUEST FOR RECONSIDERATION RECEIVED

Oct 17, 2024

TEAS REQUEST FOR RECONSIDERATION RECEIVED

TEAS AMENDMENT OF USE RECEIVED

Oct 17, 2024

TEAS AMENDMENT OF USE RECEIVED

USE AMENDMENT FILED

Oct 17, 2024

USE AMENDMENT FILED

AMENDMENT TO USE PROCESSING COMPLETE

Oct 17, 2024

AMENDMENT TO USE PROCESSING COMPLETE

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

May 23, 2024

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

May 23, 2024

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

FINAL REFUSAL WRITTEN

Apr 17, 2024

FINAL REFUSAL WRITTEN

FINAL REFUSAL E-MAILED

Apr 17, 2024

FINAL REFUSAL E-MAILED

NOTIFICATION OF FINAL REFUSAL EMAILED

Apr 17, 2024

NOTIFICATION OF FINAL REFUSAL EMAILED

TEAS RESPONSE TO OFFICE ACTION RECEIVED

Mar 18, 2024

TEAS RESPONSE TO OFFICE ACTION RECEIVED

CORRESPONDENCE RECEIVED IN LAW OFFICE

Mar 18, 2024

CORRESPONDENCE RECEIVED IN LAW OFFICE

TEAS/EMAIL CORRESPONDENCE ENTERED

Mar 18, 2024

TEAS/EMAIL CORRESPONDENCE ENTERED

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

Dec 14, 2023

APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

Dec 14, 2023

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED

NON-FINAL ACTION WRITTEN

Sep 18, 2023

NON-FINAL ACTION WRITTEN

NON-FINAL ACTION E-MAILED

Sep 18, 2023

NON-FINAL ACTION E-MAILED

NOTIFICATION OF NON-FINAL ACTION E-MAILED

Sep 18, 2023

NOTIFICATION OF NON-FINAL ACTION E-MAILED

ASSIGNED TO EXAMINER

Sep 14, 2023

ASSIGNED TO EXAMINER

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Jun 08, 2023

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

NEW APPLICATION ENTERED

May 13, 2023

NEW APPLICATION ENTERED

Other Marks by Obsidian Therapeutics, Inc.

Additional USPTO filings from the same owner.

CYT

CYTOTIL15

90710889

Obsidian Therapeutics, Inc.

REGISTERED

OBS

OBSIDIAN

86897180

Obsidian Therapeutics, Inc.

REGISTERED

OBS

OBSIDIAN THERAPEUTICS

88982707

Obsidian Therapeutics, Inc.

REGISTERED

LOG

LogoMark

88982735

Obsidian Therapeutics, Inc.

REGISTERED

Other Marks in Class 042 — Scientific, technology & SaaS services

Recently filed and registered marks in the same international class.

CYT

CYTOTIL

88667528

Obsidian Therapeutics, Inc.

ABANDONED

Other Marks by Olivia Maria Baratta

Additional USPTO filings handled by the same attorney of record.

VOI

VOICES OF BLACK WOMEN

98976615

REGISTERED

LUX

LUXEGUARD

99324107

REGISTERED

LOG

LogoMark

86160387

REGISTERED

WIL

WILDER

97586940

REGISTERED

CYTOTIL

Run a conflict check

Other Marks by Obsidian Therapeutics, Inc.

Other Marks in Class 042 — Scientific, technology & SaaS services

Other Marks by Olivia Maria Baratta

Get pre-filing clearance

Search 15M+ trademarks

Resources

Company